Amgen Analyst Likes Diversified Business, Remains Patient Until MariTide Obesity Data - Amgen (NASDAQ:AMG

Amgen approaches 52-week highs on Q3 earnings beats and raised 2026 guidance, while Wall Street analysts lift price targets.

Continue in Briflio to read, react, comment, and share.